Roche Claims Phase III Data Supports Use of Avastin in Ovarian Cancer
ICON7 trial found Avastin-chemo combo and Avastin follow-on treatment boosts PFS by 27%.!--h2>
Roche says new Phase III trial data supports the continued development of Avastin for treating ovarian cancer. Data from the ICON7 study showed that chemotherapy-naïve patients who received Avastin plus chemotherapy, followed by Avastin alone, had a 27% improvement in progression-free survival (PFS)compared with women receiving only chemotherapy. The data was presented at the recent Congress of the European Society of Medical Oncology.
The firm says the latest data supports that reported earlier this year from the pivotal Phase III trial GOG0218 in ovarian cancer patients. This study found that combining Avastin with chemotherapy and then continuing Avastin therapy resulted in a 54% increase in PFS compared with chemotherapy alone. Trial GPOG0218 evaluated a higher dose of Avastin and longer treatment duration than trial ICON7.
Roche says overall survival data from both studies has yet to be finalized, but to date favors the Avastin-containing study arms.